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Abstract: An extensive list of side effects and problems are associated with the administration 
of l-dopa (l-3, 4-dihydroxyphenylalanine) during treatment of Parkinson’s disease. These 
problems can preclude achieving an optimal response with l-dopa treatment.
Purpose: To present a case study outlining a novel approach for the treatment of Parkinson’s 
disease that allows for management of problems associated with l-dopa administration and 
discusses the scientific basis for this treatment.
Patients and methods: The case study was selected from a database containing 254 Parkinson’s 
patients treated in developing and refining this novel approach to its current state. The spectrum 
of patients comprising this database range from newly diagnosed, with no previous treatment, 
to those who were diagnosed more than 20 years before and had virtually exhausted all medical 
treatment options. Parkinson’s disease is associated with depletion of tyrosine hydroxylase, 
dopamine, serotonin, and norepinephrine. Exacerbating this is the fact that administration of 
l-dopa may deplete l-tyrosine, l-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, and 
sulfur amino acids. The properly balanced administration of l-dopa in conjunction with 5-HTP, 
l-tyrosine, l-cysteine, and cofactors under the guidance of organic cation transporter functional 
status determination (herein referred to as “OCT assay interpretation”) of urinary serotonin and 
dopamine, is at the heart of this novel treatment protocol.
Results: When 5-HTP and l-dopa are administered in proper balance along with l-tyrosine, 
l-cysteine, and cofactors under the guidance of OCT assay interpretation, the long list of 
problems that can interfere with optimum administration of l-dopa becomes controllable and 
manageable or does not occur at all. Patient treatment then becomes more effective by allowing 
the implementation of the optimal dosing levels of l-dopa needed for the relief of symptoms with-
out the dosing value barriers imposed by side effects and adverse reactions seen in the past.
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Introduction
There is a need to effectively control and manage the problems associated with l-dopa 
treatment in every Parkinson’s patient allowing full access to the l-dopa dosing level 
needed by each Parkinson’s patient in order to achieve optimal relief of symptoms.1,2
This novel approach allows for the full access to the required l-dopa dosing values 
through minimization or elimination of the undesirable l-dopa side effects. This is the 
first attempt to formally document some of the results seen and the experience gained 
in refining this novel protocol as applied to Parkinson’s disease.
Based on clinical experience gained with this novel protocol, it is asserted that 
virtually all of the problems encountered in the administration of l-dopa for Parkinson’s International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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disease are caused by the improper management of systems 
impacted by l-dopa and/or the concomitant use of carbidopa 
with l-dopa.
This case study was selected as the focal point for a dis-
cussion of a novel Parkinson’s disease treatment protocol. 
The case was not selected due to extraordinary results; it 
was selected as an illustration of typical results seen with 
this protocol. The purpose of this paper is to outline the basic 
protocol as a reference point for future prospective studies.
The patient is a Vietnam veteran working as a computer 
specialist who at the age of 55 years began to experience 
tremor in the left upper extremity, which led to the   diagnosis 
of Parkinson’s disease. The patient was referred to the 
practice of one of the authors of this paper for intravenous 
(IV) glutathione treatment by a prominent neurologist. The 
patient had exhausted virtually all nonsurgical   medical 
approaches in the treatment of his Parkinson’s disease. His 
neurologist advised him that the only remaining option 
available in the United States was deep brain stimulation. 
This option was not agreeable to the patient. 
This paper is based on research started in 1997 that 
has consistently focused on the study, interactions, and 
applications of serotonin, dopamine, and their amino 
acid precursors. The hypothesis of this writing is that the 
  majority of side effects and problems observed during 
treatment of Parkinson’s disease with l-dopa are caused by 
mismanagement of the amino acid precursors and systems 
affected by l-dopa.
Side effects and/or adverse reactions tend to be the 
  dose-limiting events associated with administration of 
only l-dopa. These include but are not limited to nausea, 
involuntary movements, and psychiatric problems.1,2 In 
order to address these l-dopa problems, medications that 
potentiate l-dopa and/or dopamine are conventionally admin-
istered. These include decarboxylase inhibitors (carbidopa),3 
dopamine agonists,4 glutamate (n-methyl-d-aspartic acid 
[NMDA])-blocking drugs,5 anticholinergics,6 MAO-B 
inhibitors,7 and COMT inhibitors.8 All of these drugs are 
second-line support drugs in comparison to the correctional 
action and potential of l-dopa.9
This novel approach for the treatment of Parkinson’s 
disease is dependent upon the administration of l-dopa in 
adequate amounts to control symptoms through minimization 
of side effects and adverse reactions by establishing a proper 
balance between the dopamine and serotonin systems with 
the concomitant use of 5-hydroxytyrptophan (5-HTP), 
l-tyrosine, and a sulfur amino acid under the guidance of 
organic cation transporter (OCT) assay interpretation.10–14
The primary symptoms of Parkinson’s disease are the 
result of degeneration of the post-synaptic neurons of 
the substantia nigra. The very process of Parkinson’s disease 
is associated with depletion of dopamine (DA), tyrosine 
hydroxylase (TH), norepinephrine (NE), and serotonin 
(5-HT).15–17 Parkinson’s disease depletion of these systems 
is compounded by further depletion with l-dopa. As noted 
in the literature, administration of only l-dopa or improperly 
balanced l-dopa further depletes:
•	 l-tyrosine13,18,19
•	 serotonin10,14,18,20–25
•	 l-tryptophan18
•	 sulfur amino acids (glutathione and S-adenosyl-
methionine)10,13,14,26–28
•	 epinephrine29
l-dopa depletion of l-tyrosine
Patients with Parkinsonism suffer from low levels of 
tyrosine hydroxylase prior to treatment.15,17 The depressed 
levels of tyrosine hydroxylase inhibit conversion of 
l-tyrosine to l-dopa. It is known that l-dopa depletes 
l-tyrosine.13,18,19 The interaction of l-tyrosine and l-dopa 
is covered in the discussion section of this manuscript. 
Other considerations of l-tyrosine depletion by l-dopa 
that need to be explored are the impact on other systems 
where l-tyrosine acts as a precursor, such as with thyroid 
hormones.
l-dopa depletion of serotonin
Patients with Parkinsonism suffer from inadequate lev-
els of serotonin as a result of the disease state.15,16 On 
  average,   Parkinson’s disease patients have a 50% deple-
tion of serotonin prior to starting treatment.16 Significant 
dosing   values of l-dopa induce the competitive inhibi-
tion state leading to further serotonin depletion through 
processes relating to interaction of serotonin and dop-
amine in synthesis, transport, and metabolism.10,14,18,20–25 
Definitive steps need to be taken during administration 
of l-dopa to keep serotonin in proper balance with 
dopamine.10,13,14
In the competitive inhibition state the serotonin and 
  catecholamine systems function as one single system (herein 
referred to as the “serotonin–dopamine system”).10–14 While 
in the competitive inhibition state changes to one component 
of the serotonin–dopamine system will effect changes to all 
components of both systems.11,14 The solution is concomitant 
administration of 5-HTP along with l-dopa to prevent the 
serotonin depletion.10,13,14International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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l-dopa depletion of sulfur amino acids
It is known that administration of l-dopa depletes   sulfur 
amino acids.10,13,14,26–28 The implications of this are   extensive. 
  Glutathione is a sulfur amino acid and a   powerful   antioxidant 
that neutralizes neurotoxins that may cause Parkinson’s 
  disease and other neurotoxic events in the body.25 Implications 
of sulfur amino acid depletion   relating to Parkinson’s disease 
include but are not limited to the depletion of:
•	 glutathione leading to progression of Parkinson’s   disease 
if the neurotoxic agents that are a component of the etiology 
are still present and being absorbed into the system25
•	 the enzymes required to synthesize l-tyrosine to 
l-dopa13,17,19
•	 s-adenosyl-methionine, the body’s one carbon methyl 
donor10,13,14,26–28
•	 epinephrine29
Carbidopa in treatment
Carbidopa is a general decarboxylase inhibitor. It   inhibits 
l-aromatic amino acid decarboxylase (AAAD), the enzyme that 
catalyzes synthesis of both serotonin and dopamine from 5-HTP 
and l-dopa, respectively. Carbidopa does not cross the blood–
brain barrier. It exerts its actions   peripherally. In   Parkinson’s 
disease it is administered to decrease   peripheral conversion of 
l-dopa to dopamine. This results in the need for a lesser dose 
of l-dopa peripherally while still giving the higher level in the 
CNS with fewer side effects, especially nausea. Carbidopa is 
used to address the side effects seen when improperly balanced 
l-dopa is administered; there is no direct therapeutic value of 
carbidopa in treatment of Parkinson’s disease.30
Carbidopa’s inhibition of AAAD potentiates   peripheral 
serotonin, dopamine, norepinephrine, and   epinephrine 
depletion as synthesis by AAAD is compromised. 
  Norepinephrine and acetylcholine regulate autonomic 
nervous system function. The administration of carbidopa 
with l-dopa is replete with peripheral autonomic dysfunction 
problems that often develop.30
Administration of carbidopa/l-dopa preparations leads 
to a “double depletion” of peripheral serotonin. One cause 
of depletion is carbidopa inhibition of AAAD; the other 
cause is improperly balanced administration of l-dopa 
which decreases peripheral serotonin synthesis and transport 
through competitive inhibition along with increasing the 
metabolism of serotonin.10,13,14
Materials and methods
Organic cation transporter functional status determination 
(herein referred to as “OCT assay interpretation”) along 
with the amino acid dosing values described in this paper 
were developed by NeuroResearch Clinics, Inc (Duluth, 
MN). All of the amino acid components, including l-dopa, 
are available over the counter without a prescription in the 
United States.
Treatment was initiated with administration of 5-HTP, 
l-tyrosine, and l-dopa at the dose levels shown in Table 1. 
In addition to the amino acids noted in Table 1, the following 
cofactors were administered daily: 1) vitamin C 1,000 mg; 
2) calcium citrate 220 mg; 3) vitamin B6 75 mg; 4) folate 
400 mcg; 5) l-lysine 500 mg; 6) l-cysteine 4,500 mg; 
7) selenium 400 mcg.
l-dopa in the form of mucuna pruriens 40% standardized 
was used. Peer-reviewed literature suggests that l-dopa from 
the mucuna pruriens source has more rapid onset of action 
and a longer time of effectiveness leading to the conclusion 
that it may be a superior source of l-dopa in treating 
  Parkinson’s disease.31
OCT assay interpretation overview
Serotonin and dopamine are found in two states. The 
endogenous state exists when no amino acid precursors are 
administered. The competitive inhibition state occurs when 
significant amounts of the monoamine precursors are 
simultaneously administered. Proper OCT assay interpretation 
requires that both serotonin and dopamine be placed in the 
competitive inhibition state prior to the assay interpretation 
being performed for the results to be valid.
The scientific basis for OCT assay interpretation is novel 
having been published in 2009 and 2010. At the heart of this 
approach is the “3-phase model.”10–14,32
The goal of this novel approach is to keep the urinary 
serotonin in the phase III therapeutic range, no higher 
than 800 µg serotonin per gram of creatinine, through 
proper manipulation of 5-HTP in combination with 
l-dopa dosing values under the guidance of OCT assay 
interpretation.3,7,8,19,20
Table 1 Parkinson’s dosing values at protocol initiation. serotonin 
and dopamine precursors initially administered. One week after 
start of the second dosing level, a urine sample was obtained for 
OCT assay interpretation
mg 5-hydroxytryptophan (5-HTP)/mg L-tyrosine/mg L-dopa
Morning Noon 4 pm
Initial visit 150/1,500/120 – 150/1,500/120
7 days into treatment 150/1,500/360 0/0/240 150/1,500/360
14 days into treatment Initiate organic cation transporter assay 
interpretationInternational Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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To facilitate replication of results the following data is 
included. Processing, management, and assay of the urine 
samples collected for this study were as follows. Urine 
samples were collected about 6 hours prior to bedtime with 
4:00 pm being the most frequent collection time point. The 
samples were stabilized in 6 N HCl to preserve the   dopamine 
and serotonin. The urine samples were collected after a 
minimum of 1 week during which time the patient was taking 
a specific daily dosing of amino acid precursors of serotonin 
and dopamine where no doses were missed.   Laboratory 
studies were conducted by DBS Laboratories under the 
direction of Thomas Uncini, MD, one of the authors. The 
assays were performed using commercially available radio-
immunoassay kits from Immunol Biological Laboratories, 
Inc (Minneapolis, MN). Assays were interpreted by Marty 
Hinz of NeuroResearch Clinics.
evaluation of treatment results
The Unified Parkinson’s Disease Rating Scale (UPDRS) 
on presentation into the practice and before the start of the 
protocol as compared to the results 2 years into the amino 
acid treatment is seen in Table 2.
Results
The only portion of the patient’s history that seems relevant 
to the etiological factors involved in the development of the 
Parkinson’s disease was his exposure to Agent Orange during 
the course of his tour of duty in Vietnam while serving in the 
military. Agent Orange is a known neurotoxin.
Early in the patient’s clinical course the symptoms were 
mild and untreated. As the symptoms increased in the left 
upper extremity he was prescribed carbidopa–levodopa. The 
patient was opposed to taking the carbidopa–levodopa at 
that time and pursued alternative medicine options. Over the 
next 18 months, the patient was treated with IV glutathione, 
amantadine, trihexyphenidyl, primidone, and propranolol.
The amantadine gave no relief. The trihexyphenidyl 
was given in an attempt to relieve the tremor, but the tremor 
continued to progress extending into the patient’s left 
lower extremity compounded by severe balance and gait 
issues. Primidone provided some relief from the tremor, 
but it caused severe nausea requiring discontinuance of the 
medication. Propranolol provided no relief. IV glutathione 
was effective in diminishing the tremor, but results lasted 
only about 30 hours.
The patient was then again prescribed carbidopa–
levodopa in combination, which was completely ineffective. 
It was also suggested by that physician that the patient seek 
out additional IV glutathione treatments nearer to his home 
as that was the only approach that achieved some relief of 
symptoms.
In October 2008, the patient presented at the practice of 
one of the authors of this paper for IV glutathione treatment. 
The patient was having increasing difficulty with every aspect 
of life. He was very self-conscious of the constant tremor 
in his left arm and left leg, which interfered with sleep and 
sitting comfortably in a chair, and made him feel conspicuous 
in public. He was having great difficulty working at his job 
as a computer specialist for a large computer corporation 
and found it almost impossible to type on a keyboard or 
to maintain focus during conference calls. He was also 
experiencing severe anxiety, depression, panic attacks, and 
insomnia.
On the first visit it was apparent that IV glutathione had 
not achieved any meaningful or lasting relief of symptoms in 
the past and that it was another brief band-aid approach to the 
disease. After obtaining a comprehensive medical history and 
performing a physical examination the patient was offered 
the novel treatment approach discussed in this report. The 
use of comprehensive amino acid support in conjunction with 
OCT assay interpretation was discussed with the patient and 
he agreed to the treatment plan.
Within 4 months of initiating treatment the patient 
experienced dramatic improvement in the tremor in both 
the upper and lower extremities. He regained coordination 
in his left hand and was once again able to use the computer 
keyboard. He resumed his hobby of guitar playing and was 
able to perform proficiently. His gait and balance were 
restored. The depression improved significantly. Anxiety 
was significantly relieved. The patient had lost his fear of 
going out in public.
In the 2 years since initiation of treatment the patient has 
continuously maintained the benefit of the treatment, with 
no surgical intervention as previously recommended by his 
neurologist and no prescription medications.
There appears to have been some progression of the 
damage associated with the Parkinson’s neurons since 
Table 2 Unified Parkinson’s disease rating scale (UPDRS)33
Start of  
treatment
2 years into treatment   
with amino acids
Mentation behavior mood 9 0
Daily activities of living 16 3
Motor examination 16 0
Complications of therapy 1 0
Totals 42 3International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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initiation of treatment, as there has been a need for increasing 
the dosage of the l-dopa. This has been managed by 
increasing the l-dopa dosing value while continuing to moni-
tor the balance of the levels with OCT assay interpretation. 
The reason for asserting that this represented a progression 
of disease state versus tachyphylaxis of l-dopa, which is 
commonly seen during treatment of Parkinson’s disease, is 
covered in the Discussion section.
The amino acid dosing that the patient was taking at the 
initiation of this study, 2 years after starting on the program, 
is found in Table 3.
The amino acid dosing values administered in treatment 
were guided by OCT assay interpretation to assist in proper 
titration of the levels of l-dopa, l-tyrosine, and 5-HTP. This 
assured that the patient achieved proper therapeutic levels of 
amino acids while keeping serotonin and dopamine in the 
proper balance required for minimization of side effects and 
adverse reactions while optimizing outcomes. The urinary 
serotonin and dopamine levels obtained during stabilization 
of the patient were as shown in Table 4.
At the April 29, 2010 collection date sample of Table 4, 
the patient was suffering from nausea and on–off effect 
secondary to serotonin imbalance and inadequate l-tyrosine 
administration, respectively. The nausea improved by the May 
18, 2010 collection date sample. Subsequent to the May 18, 
2010 collection date the l-tyrosine was increased incremen-
tally to 10,375 mg per day and the l-dopa was gradually 
lowered. By mid-June, the nausea and on–off effect became 
minimal.
Discussion
etiology of the disease
The literature is clear that l-dopa holds the highest potential 
for relief of symptoms, but dosing values in many patients 
are limited by side effects.9 With administration of l-dopa, 
side effects and adverse reactions may be the dose-limiting 
event that prevents attaining optimal dosing values. The 
following discussion is aimed at defining the basis for an 
effective treatment that controls the problems associated with 
l-dopa administration.
There are a host of problems encountered in group 
treatment with l-dopa that have not been displayed in this 
patient’s course of treatment.1,30 Future prospective studies 
under this protocol are indicated to define a more exact 
incidence of each of these events and their impacts on 
treatment.
While this is a case study report, the authors of this 
paper possess data on the amino acid dosing needs of 
over 254   Parkinson’s patients who have been treated 
in the refinement of this novel approach to its current 
state. At the core of this approach is the administra-
tion of l-dopa, which is approved by the US Food and 
Drug Administration (FDA) for treatment of Parkinson’s 
  disease. Table 5 lists the group dosing ranges of 5-HTP and 
l-dopa seen during refinement of this novel Parkinson’s 
disease treatment approach with the guidance of OCT 
assay interpretation.
As noted in Table 5, dosing value needs are highly 
individualized. Group dosing value needs of l-dopa and 
5-HTP to control the symptoms vary in exceptionally 
large ranges. The l-dopa dosing value found in the “high” 
  column of Table 5 has not been described previously in the 
literature for the treatment of Parkinson’s disease. It appears 
that adverse reactions have precluded reaching these dosing 
values in the past.
The chief dose-limiting factor tends to be nausea.2 Our 
experience indicates that the only way a patient can safely 
and effectively be titrated to the high l-dopa dosing values 
found in Table 5 is with OCT assay interpretation guiding 
amino acid dosing values.
In Table 3 of this case study the daily l-dopa dosing value 
of 14,700 mg per day is large. The authors of this paper were 
unable to locate previous literature discussing this type of 
dosing value being routinely available to patients if needed 
without seeing a problem significant enough to cut back the 
treatment below the therapeutic threshold. Review of the 
  literature reveals that a significant group of patients develop 
the gastrointestinal (GI) side effects that limit further increases 
in l-dopa with dosing values in the 3,000 to 4,000 mg per 
day range. Certainly there are Parkinson’s patients that need 
much more than 3,000 to 4,000 mg per day of l-dopa, but 
these patients are barred from the optimal treatment benefits 
of l-dopa as a result of the side effects.1,2
The huge dosing variance seen during group treatment 
of the Parkinson’s patients in Table 5 shows that one-size 
dosing does not fit all.
Table 3 The current amino acid dosing values that the patient 
is taking, plus cofactors found in the discussion associated with 
Table 1
Present daily amino acid dosing values in mg/day
L-dopa 14,700
5-HTP 37.5
l-tyrosine 10,375
l-cysteine 4,500
l-tryptophan 375International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Management of L-dopa depletion  
of serotonin
The serotonin depletion symptoms seen in   Parkinson’s disease 
and l-dopa administration fall into three   categories: 1)   disease 
symptoms associated with inadequate   serotonin   levels; 
2) side effects and adverse reactions; and 3) tachyphylaxis 
of l-dopa.
Depression is a prominent disease associated with 
inadequate serotonin levels in Parkinson’s disease patients 
during treatment with l-dopa. Proof of this is the response to 
the most selective serotonin reuptake inhibitor, citalopram.34 
Other monoamine-related disease symptoms resulting from 
depletion of serotonin by the disease and l-dopa are covered 
in the following discussion.10–13
Simply administering some 5-HTP with l-dopa is not 
optimal. When serotonin levels that are too high in phase 
III depletion of dopamine may occur through competitive 
inhibition.10,14,35,36 Nausea associated with the administration 
of l-dopa is a sign of serotonin and dopamine imbalance. If 
serotonin levels are too high or too low, nausea from l-dopa 
can become a significant problem. When 5-HTP and l-dopa 
are in proper balance and nausea associated with l-dopa dis-
plays, it is much milder and more easily manageable, resolving 
in a matter of days in most cases. Additional management of 
residual nausea may be through the implementation of smaller, 
more frequent l-dopa dosing values. With proper serotonin–
dopamine balance nausea is no longer an l-dopa dose-limiting 
event for virtually all patients and the use of carbidopa is no 
longer needed. Since the development of nausea is the result 
of serotonin levels that are either too high or too low and the 
high or low status of the serotonin relative to dopamine can-
not be distinguished clinically, OCT assay interpretation is 
indicated to properly clarify and manage the problem.
Even with judicious and generous use of OCT assay 
interpretation in this case study, this patient developed some 
transient nausea, but it was not significant enough to avoid 
maintaining the l-dopa dosing values at the level needed for 
continued relief of Parkinson’s symptoms or the stopping 
of the l-dopa, and within a matter of days the symptoms 
resolved.10–14
Tachyphylaxis (where a drug stops working) of l-dopa 
is associated with depletion of serotonin by l-dopa. When 
serotonin levels become too depleted, any beneficial effects 
of l-dopa will not be observed regardless of how high the 
l-dopa dosing values are raised. When tachyphylaxis occurs, 
the typical response is to increase the daily l-dopa dosing 
value, which only further depletes serotonin. As treatment 
Table 4 serotonin and dopamine values reported in µg of monoamine per g of creatinine. Amino acid dosing values reported in mg/day
1  
Date
2  
Serotonin
3  
Serotonin phase
4  
Dopamine
5  
Dopamine phase
6  
5-HTP
7  
L-tyrosine
8  
L-dopa
10/23/2008 1,309.1 3 345.8 2 200.0 1,500 300
10/30/2008 1,882.1 3 341.4 2 200.0 3,000 300
11/6/2008 7,506.8 3 792.9 3 300.0 3,000 450
11/18/2008 3,962.9 3 1,212.2 3 100.0 3,000 1950
12/11/2008 2,192.5 3 1,364.7 3 100.0 4,500 3600
1/8/2009 106.7 3 1,900.6 3 37.5 4,500 6300
1/22/2009 399.9 3 1,170.8 3 37.5 4,500 6300
2/12/2009 202.1 3 1,747.7 3 37.5 4,500 8400
3/19/2009 1,175.8 3 1,489.9 3 100.0 4,500 15,750
4/13/2009 395.2 3 1,149.9 3 100.0 4,500 12600
6/1/2009 386.3 3 1,814.6 3 37.5 4,875 11,550
6/18/2009 130.2 3 1,729.7 3 37.5 4,875 12,600
7/28/2009 84.9 3 2,915.7 3 37.5 4,875 12,600
9/8/2009 386.3 3 1,730.0 3 37.5 3,875 12,600
1/7/2010 710.2 3 2,029.8 3 75.0 5,750 14,700
4/29/2010 4,848.6 3 1,346.0 3 212.5 7,125 13,350
5/18/2010 724.9 3 1,505.7 3 37.5 6,375 14,700
Notes: 1) Date of urine sample collection; 2) urinary serotonin reported; 3) serotonin phase; 4) urinary dopamine reported; 5) dopamine phase; 6) 5-HTP dosing value at 
time of sample collection; 7) l-tyrosine dosing value at time of sample collection; 8) L-dopa dosing value at time of sample collection.
Table 5 5-HTP and L-dopa group dosing parameters based on OCT 
assay interpretation during treatment N = 714. 5-HTP and L-dopa 
dosing value range (low-high), mean, and standard deviation
Low High Mean SD
5-HTP 37.5 mg 2,100 mg 300 mg 330.3 mg
L-dopa 120 mg 25,230 mg 1,680 mg 3,652 mg
Note: OCT assay interpretation refers to organic cation transporter functional status 
determination.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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progresses, with further increases of the l-dopa dosing 
  values, the time between tachyphylaxis events decreases 
and the patient’s l-dopa dosing values spiral ever higher. 
The indicated approach is OCT assay interpretation in order 
to balance serotonin and its precursors with the l-dopa and 
dopamine, thereby managing the problem effectively.10–14
The results section noted a decrease in effectiveness 
in the l-dopa in this patient in early 2009. In the results 
section it was asserted, “There appears to have been some 
progression of the damage associated with the Parkinson’s 
neurons since the initiation of treatment, as there has been 
a need for increasing the dosage of the l-dopa. This has 
been managed by increasing the l-dopa dosing value while 
continuing to monitor the balance of the levels with OCT 
assay interpretation.” The decreased effectiveness of l-dopa is 
primarily due to one of three events: 1) lack of patient compli-
ance; 2) serotonin depletion leading to l-dopa tachyphylaxis; 
or 3) further neuronal damage causing progression of the 
disease. The patient’s medication journal ruled out concerns 
in the area of compliance. OCT assay interpretation revealed 
that the urinary serotonin was in phase III and in the desired 
range, ruling out serotonin depletion concerns associated 
with l-dopa tachyphylaxis. By exclusion, further progres-
sion of disease in the form of progression of neuronal dam-
age had occurred. The three primary causes of decreased 
response to prescribing l-dopa noted in this paragraph need 
to be fully appreciated and implemented since the treatment 
approach to the perceived decrease in efficacy of l-dopa is 
very different.
Management of dopamine fluctuations 
with l-tyrosine
As noted in previous writings by two of the authors of this 
paper, urinary dopamine levels fluctuate on urinary assay sig-
nificantly if proper levels of l-tyrosine are not   co-  administered 
with l-dopa in the competitive inhibition state.37 This fluctua-
tion in the competitive inhibition state is a direct reflection 
of OCT2 activity of the basolateral monoamine transporters 
of the proximal convoluted tubule cells of the kidneys.11,38 
Research experience leading up to this writing has shown that 
patients taking l-dopa required minimum administration of 
5,000 to 6,000 mg per day of l-tyrosine to prevent significant 
urinary dopamine fluctuations.10,13 It is a novel finding of this 
research that l-tyrosine depletion and dopamine fluctuations 
are associated with the on–off effect. The patient in this study 
began to experience on–off effect. Instead of increasing the 
l-dopa dosing, the l-tyrosine dosing values were increased 
as noted in Table 3. The maximum required l-tyrosine dos-
ing value encountered for control of on–off effect in all 
patients studied leading up to the writing of this paper was 
20,000 mg per day.
Management of sulfur amino acid 
depletion by l-dopa
The sulfur amino acid l-cysteine was selected for use due 
to its role in synthesis of enzymes that catalyze monoamine 
synthesis. Theoretically, from the standpoint of enzymes 
that catalyze monoamine synthesis, any sulfur amino acid, 
with the exception of n-acetyl-cysteine and glutathione, may 
serve as a sulfur donor in enzyme synthesis. From a database 
developed by one of the authors of this article containing 
over 1.931 million patient-days of amino acid treatment in 
patients not suffering from Parkinson’s disease, objective 
results revealed optimal l-cysteine dosing was 4,500 mg 
per day. No objective changes were observed with the daily 
dosing values of l-cysteine at or below 2,250 mg per day and 
no additional response was seen in dosing values greater than 
4,500 mg per day.10,13,14
Administration of proper levels of sulfur amino acids 
prevents depletion of all of the following: glutathione; the 
enzymes that catalyze amino acid precursors into monoamines; 
S-adenosylmethionine; and epinephrine.10,13,14
It is asserted that metabolism of toxins utilizes a large 
amount of sulfur amino acids in the form of glutathione 
each day. Administration of IV glutathione is analogous 
to temporarily plugging a hole in a bucket leaking sulfur 
amino acids. The effect of IV glutathione is a temporary 
band-aid approach, with sulfur amino acid levels returning 
to the previous state and a relapse of symptoms within one to 
two days of administration. A superior approach is the daily 
administration of proper levels of sulfur amino acids from 
the start of treatment so that sulfur amino acid depletion does 
not have to be further addressed.10,13,14
Management of paradoxical amino acid  
reactions
Most Parkinson’s disease patients treated under this novel 
approach do not achieve gradual relief of symptoms as the 
l-dopa dosing values are increased. Symptom cessation 
tends to be abrupt, analogous to turning a light switch from 
off to on.10,13,14
Paradoxical reactions with concomitant administration 
of serotonin and dopamine amino acid precursors occur 
in approximately 5% of patients. A paradoxical reaction is International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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defined as an outcome to treatment that is the opposite of what 
is expected. In the Parkinson’s disease patients being treated 
with balanced amino acid precursors, the most common 
paradoxical reactions are agitation and confusion, although 
any disease process related to monoamine diseases may be 
exacerbated such as depression, insomnia, or anxiety. With 
most Parkinson’s disease patients, paradoxical reactions occur 
after many weeks or months when the l-dopa dosing value 
is on the threshold needed for control of Parkinson’s disease 
symptoms late in treatment.10,13,14
Achieving the results noted in this case study is 
dependent upon proper management of any paradoxical 
reactions that may develop and being able to differentiate 
a paradoxical reaction from a side effect or adverse reac-
tion. Proper management of paradoxical reactions in the 
Parkinson’s patient is to adequately increase the l-dopa 
dosing value. With a proper increase, the paradoxical 
reaction will resolve in 1 to 2 days. Physicians who are 
not properly oriented to the management of paradoxical 
reactions may tend to inappropriately decrease the l-dopa 
dosing when a paradoxical reaction displays, then increase 
the l-dopa dosing slowly. This approach only leads to the 
patient being exposed to the l-dopa dosing range that 
induced the paradoxical reaction for a prolonged period 
of time and may lead to failure when symptoms of a 
paradoxical reaction are observed for a prolonged period 
of time causing the l-dopa dosing value to be decreased 
further or stopped.10,13,14
Categorizing symptoms associated  
with carbidopa/l-dopa administration
The FDA-approved prescribing information for carbidopa/ 
l-dopa preparations was reviewed and a list of side effects, 
adverse reactions, and problems associated with adminis-
tration was generated.34 Each side effect was then placed 
in one or more of the general categories listed below by 
the authors of this paper. While the listing of each side 
effect may be open to further discussion, these are the 
categories that have evolved in this research project since 
2001. The six categories of carbidopa/l-dopa side effects 
are as follows:
Category 1: Problems caused by depletion of serotonin by 
l-dopa: Tachyphylaxis (the l-dopa stops working).
Category 2: Problems caused by imbalance of serotonin 
and dopamine: Nausea, vomiting, anorexia, weight loss, 
decreased mental acuity, depression, psychotic episodes 
including   delusions, euphoria, pathologic gambling, 
impulse control, confusion, dream abnormalities including 
nightmares,   anxiety, disorientation, dementia, nervousness, 
insomnia, sleep disorders, hallucinations and paranoid 
ideation, somnolence, memory impairment, and increased 
libido.
Category 3: Problems caused by dopamine fluctuations 
due to inadequate tyrosine levels: On-off effect, motor 
fluctuations, dopamine fluctuations, implicated as an etiology 
of dyskinesia.
Category 4: Problems caused by depletion of   sulfur amino 
acids by l-dopa: Bradykenesia (epinephrine   depletion 
implicated), akinesia, dyskinesia, dystonia, chorea, 
  extrapyramidal side effects, fatigue, abnormal involuntary 
movements, and depletion of glutathione potentiating further 
dopamine neuron damage by neurotoxins.
Category 5: Problems caused by paradoxical amino acid 
  reactions: Confusion, dizziness, headache,   palpitations, 
dyspnea, anxiety, agitation, increased tremor, faintness, 
exacerbation of any disease related to the monoamine 
(serotonin, dopamine, norepinephrine, and epinephrine) 
neurotransmitters, and exacerbation of any central disease 
process associated with the serotonin and catecholamine 
systems.
Category 6: Peripheral problems caused by peripheral depletion 
of serotonin and catecholamines by carbidopa: Glossitis, leg 
pain, ataxia, falling, gait abnormalities, blepharospasm (which 
may be taken as an early sign of excess dosage), trismus, 
increased tremor, numbness, muscle twitching, peripheral 
neuropathy, myocardial infarction, flushing, oculogyric crises, 
diplopia, blurred vision, dilated pupils, urinary retention, urinary 
incontinence, dark urine, hoarseness, malaise, hot flashes, sense 
of stimulation, dyspepsia, constipation, palpitation, fatigue, 
upper respiratory infection, bruxism, hiccups, common cold, 
diarrhea, urinary tract infections, urinary frequency, flatulence, 
priapism, pharyngeal pain, abdmoninal pain, bizarre breathing 
patterns, burning sensation of tongue, back pain, shoulder pain, 
chest pain (noncardiac), muscle cramps, paresthesia, increased 
sweating, falling, syncope, orthostatic hypotension, asthenia 
(weakness), dysphagia, Horner’s syndrome, mydriasis, dry 
mouth, sialorrhea, neuroleptic malignant syndrome, phlebitis, 
agranulocytosis, hemolytic and nonhemolytic anemia, rash, 
gastrointestinal bleeding, duodenal ulcer, Henoch-Schonlein 
purpura, decreased hemoglobin and hematocrit, thrombocy-
topenia, leukopenia, angioedema, urticaria, pruritus, alopecia, 
dark sweat, abnormalities in alkaline phosphatase, abnormali-
ties in SGOT (AST), SGPT (ALT), abnormal Coombs’ test, 
abnormal uric acid, hypokalemia, abnormalities in blood urea 
nitrogen (BUN), increased creatinine, increased serum LDH, 
and glycosuria.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Conclusion
The Parkinson’s disease process is known to be   associated with 
depletion of serotonin, tyrosine hydroxylase, norepinephrine, 
and dopamine. l-dopa is known to deplete serotonin, 
  serotonin precursors, tyrosine, and the sulfur amino acids. 
The dosing range of serotonin precursors needed for the 
individual patient to achieve proper balance with l-dopa 
administration appears to be in a relatively narrow range with 
some of the side effects being displayed if the serotonin is 
either too high or too low.
The most prominent dose-limiting events in the use of 
l-dopa are the GI symptoms of nausea and vomiting along 
with psychiatric problems. The patient in this case study had 
the l-dopa, 5-HTP, l-tyrosine, and l-cysteine administered in 
proper balance. OCT assay interpretation was implemented 
early in order to get out in front of amino acid imbalance 
problems before they occurred.
Everything used in the treatment of this patient is 
recognized by the FDA as GRAS (generally regarded as 
safe) and available over the counter without a prescription 
in the United States.
This paper is the product of nine years of research in the 
area of serotonin and dopamine precursor administration as 
guided by OCT assay interpretation and statistical analysis 
of numerous large databases. The protocol has been refined 
since 2001 and appears ready for prospective studies. This 
paper is an attempt to document what is known prior to 
further studies.
The goal of this paper is to share some of the knowledge 
gained prior to expanding group studies, spark interest in this 
area of research, and hold these observations up to scrutiny 
for Parkinson’s disease patients and their caregivers. The 
administration of properly balanced amino acid precursors 
used here for Parkinson’s disease does hold potential in 
other research areas as evidenced by previous peer-reviewed 
writings of the authors since 2009.
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